Imugene Ltd has released a press release.
Imugene: Half Year Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Intellectual Property Strengthened Around Lead Clinical Drug
- BMC Cancer journal publishes encouraging HER-Vaxx research
- Imugene progresses mimotope platform
- Response to ASX Aware Query
- Acquisition of immuno-oncology technology
Later from Imugene
- $1.35 million Options Underwritten
- IMU Raises $3.0m from Options Plan
- Appendix 4C - quarterly and Commentry Q3
- Imugene granted Canadian patent for Her-Vaxx cancer vaccine
- First Patient Dosing Commences of HER-Vaxx
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene